within Pharmacolibrary.Drugs.ATC.N;

model N02BG10
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.1,
    Cl             = 0.5 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 10 / 1000000,
    adminCount     = 1,
    Vd             = 0.01,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0005,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Cannabinoids are a class of diverse chemical compounds that act on cannabinoid receptors in cells that alter neurotransmitter release in the brain. Examples include tetrahydrocannabinol (THC) and cannabidiol (CBD). They are used for medical and recreational purposes, such as pain management, antiemetic effects, and in some countries, as adjunct therapy for spasticity in multiple sclerosis. Pharmaceutical use and approval status vary worldwide; some formulations are approved for specific indications.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for adults with reference to existing literature on THC and nabilone, administered orally.</p><h4>References</h4><ol><li><p>Grotenhermen, F (2003). Pharmacokinetics and pharmacodynamics of cannabinoids. <i>Clinical pharmacokinetics</i> 42(4) 327–360. DOI:<a href=&quot;https://doi.org/10.2165/00003088-200342040-00003&quot;>10.2165/00003088-200342040-00003</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12648025/&quot;>https://pubmed.ncbi.nlm.nih.gov/12648025</a></p></li><li><p>Moore, CF, et al., &amp; Bonn-Miller, MO (2023). Pharmacokinetics of Oral Minor Cannabinoids in Blood and Brain. <i>Cannabis and cannabinoid research</i> 8(S1) S51–S61. DOI:<a href=&quot;https://doi.org/10.1089/can.2023.0066&quot;>10.1089/can.2023.0066</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37721988/&quot;>https://pubmed.ncbi.nlm.nih.gov/37721988</a></p></li><li><p>Aran, A, et al., &amp; Castellanos, FX (2021). Cannabinoid treatment for autism: a proof-of-concept randomized trial. <i>Molecular autism</i> 12(1) 6–None. DOI:<a href=&quot;https://doi.org/10.1186/s13229-021-00420-2&quot;>10.1186/s13229-021-00420-2</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33536055/&quot;>https://pubmed.ncbi.nlm.nih.gov/33536055</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end N02BG10;
